PharmaResearch Co., Ltd. (KOSDAQ: 214450)

PharmaResearch Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	95,075	67,245	72,931	41,674	26,715	19,738
Short-Term Investments	77,503	56,549	67,989	2,000	8,981	3,000
Trading Asset Securities	33,496	36,505	43,423	113,123	43,571	46,292
Cash & Short-Term Investments	206,074	160,298	184,343	156,798	79,267	69,029
Cash Growth	7.61%	-13.04%	17.57%	97.81%	14.83%	-8.44%
Accounts Receivable	32,339	31,400	32,304	27,741	22,827	20,197
Other Receivables	2,993	3,301	2,757	975.32	873.4	375.03
Receivables	37,123	35,998	36,234	30,490	26,343	20,572
Inventory	53,282	50,232	24,453	17,342	20,781	13,928
Prepaid Expenses	956.86	1,191	667.94	701.54	373.73	97.21
Other Current Assets	14,688	8,746	1,647	1,460	639.42	846.03
Total Current Assets	312,123	256,465	247,345	206,792	127,404	104,473
Property, Plant & Equipment	138,391	123,061	117,960	109,481	94,046	73,886
Long-Term Investments	90,167	96,951	40,718	44,911	42,511	39,356
Goodwill	11,652	11,652	13,810	16,764	12,492	13,738
Other Intangible Assets	19,113	18,709	22,720	24,825	26,233	29,806
Long-Term Deferred Tax Assets	5,687	4,476	8,667	3,166	3,162	2,292
Long-Term Deferred Charges	1,377	1,614	1,297	1,200	578.13	-
Other Long-Term Assets	19,802	18,415	21,105	15,715	13,407	2,752
Total Assets	601,474	535,281	478,055	427,647	319,831	269,925
Accounts Payable	10,208	2,831	3,527	2,939	1,876	5,359
Accrued Expenses	1,410	974.34	860.08	702.95	533.87	492.04
Short-Term Debt	31,784	32,345	18,867	18,873	17,854	1,236
Current Portion of Long-Term Debt	-	33.3	87.4	726.52	610	1,913
Current Portion of Leases	1,343	628.25	1,620	1,161	1,117	358.34
Current Income Taxes Payable	15,449	11,357	10,136	6,851	6,222	3,584
Current Unearned Revenue	23.83	27.69	11.36	-	-	-
Other Current Liabilities	24,603	17,703	19,144	16,751	7,637	5,648
Total Current Liabilities	84,821	65,899	54,253	48,005	35,849	18,590
Long-Term Debt	208.24	970.72	45,359	43,385	10,505	16,496
Long-Term Leases	1,717	329.91	835.48	1,466	2,324	939.83
Long-Term Deferred Tax Liabilities	2,602	2,794	3,741	4,514	4,746	5,404
Other Long-Term Liabilities	1,604	1,911	1,648	1,175	1,133	72.86
Total Liabilities	92,366	73,087	106,399	99,288	55,420	41,502
Common Stock	5,207	5,160	5,056	5,056	4,895	4,777
Additional Paid-In Capital	183,392	175,428	157,582	152,413	133,405	126,652
Retained Earnings	299,725	260,787	190,862	154,018	112,615	82,783
Treasury Stock	-4,638	-4,638	-5,260	-5,260	-5,260	-5,260
Comprehensive Income & Other	-2,933	-3,633	-4,737	-785.15	-232.35	121.9
Total Common Equity	480,751	433,104	343,503	305,442	245,423	209,075
Minority Interest	27,549	29,091	28,153	22,917	18,989	19,349
Shareholders' Equity	509,107	462,195	371,656	328,359	264,411	228,424
Total Liabilities & Equity	601,474	535,281	478,055	427,647	319,831	269,925
Total Debt	35,052	34,307	66,768	65,611	32,410	20,943
Net Cash (Debt)	171,022	125,991	117,575	91,187	46,857	48,087
Net Cash Growth	21.85%	7.16%	28.94%	94.61%	-2.56%	-12.67%
Net Cash Per Share	15902.56	11931.85	11785.88	9070.92	4928.76	5095.13
Filing Date Shares Outstanding	10.29	10.2	9.98	9.98	9.65	9.42
Total Common Shares Outstanding	10.29	10.2	9.98	9.98	9.65	9.42
Working Capital	227,302	190,566	193,092	158,787	91,555	85,883
Book Value Per Share	46706.30	42459.18	34433.24	30617.96	25424.37	22197.68
Tangible Book Value	449,986	402,743	306,974	263,854	206,698	165,531
Tangible Book Value Per Share	43717.33	39482.74	30771.48	26449.11	21412.71	17574.63
Land	18,617	18,617	18,617	14,064	14,064	7,081
Buildings	81,758	81,472	80,151	52,235	52,135	45,537
Machinery	45,618	41,375	30,766	27,162	22,544	21,806
Construction In Progress	26,849	12,459	12,200	32,985	16,386	9,515

Source: S&P Capital IQ. Standard template. Financial Sources.